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IntroductIon
Stroke is the third most common cause of death in 
Scotland and accounts for approximately 5% of total UK 
NHS costs.1 Thrombolytic therapy using intravenous 
alteplase is currently the only licensed therapy for acute 
ischaemic stroke (AIS). The most recent meta-analysis of 
thrombolysis for AIS demonstrates a 9.0% decrease in 
death and 4.2% decrease in dependency (defined as a 
modified Rankin Score of 3 to 62) three months after 
stroke, when thrombolysis is given in the first three or 
six hours of symptom onset compared to control.3 
However, the leading complication of thrombolysis is the 
development of  symptomatic intracerebral haemorrhage 
(SICH), which carries significant morbidity and mortality. 
Of those thrombolysed, 7.7% developed  SICH, compared 
to 1.8% in control groups, with SICH accounting for 
most of the early deaths in the thrombolysed groups.3
This complication could be minimised if physicians could 
reliably predict which AIS patients might develop SICH 
after thrombolysis. Several studies have developed risk 
scores to try and estimate which patients are most at 
risk of SICH post-thrombolysis to inform thrombolysis 
decision making (e.g. the SEDAN, HAT, GRASPS and SITS 
scores4-7). The aim of the current study was to test the 
performance of these scores and to see which was most 
valid in a population treated by a single stroke centre.
Methods
Study population
Patients admitted to Aberdeen Royal Infirmary with a 
diagnosis of acute ischaemic stroke who were 
thrombolysed between 2003 and 2013 (majority enrolled 
from 2009 onwards) were entered in the Safe 
Implementation of Treatment in Stroke (SITS) database 
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(n=431). This is a European-wide database for monitoring 
the safety of thrombolysis use in ischaemic stroke 
patients.8 Patients are entered as part of clinical audit 
and information collected includes age, gender, pre-
stroke functional status (modified Rankin score), 
comorbidity, glucose, blood pressure and stroke severity 
(National Institutes of Health Stroke Scale – NIHSS9) at 
0 hours, 2 hours, 24 hours and 7 days post-thrombolysis, 
plus findings from the initial and 24 hour post-
thrombolysis CT scan. The latter includes presence of 
intracerebral haemorrhage (ICH) as previously 
described.7 This anonymised audit was approved by our 
local ethics committee.
SICH risk prediction scores
Four prediction scores were used in this study – SEDAN 
(blood Sugar, Early ischaemic changes, hyperDense 
artery sign, Age, and NIH Stroke Scale score), 
haemorrhage after thrombolysis (HAT), GRASPS 
(Glucose at presentation, Race [Asian], Age, Sex [male], 
systolic blood Pressure at presentation, and Severity of 
stroke at presentation [NIHSS] score) and SITS. Table 1 
lists the various components of each risk score.4-7 With 
respect to the HAT score, it should be noted that to 
quantify the extent of early ischaemic change in the 
middle cerebral artery (MCA) territory, the Alberta 
Stroke Programme Early Computerised Tomography 
Score (ASPECTS) was utilised. This score evaluates ten 
anatomical sites within the MCA territory for signs of 
ischaemic change and produces a normal maximum 
score of 10 (no ischaemic changes), minus one point for 
each area with ischaemic changes.10 In this study, it was 
assumed that an ASPECTS score of ≤ 7 denoted MCA 
territory hypodensity of > 1/3. 
SICH definitions
SICH has numerous definitions. This study utilised only 
those definitions which are used by the respective SICH 
risk prediction scores. The SEDAN and HAT scores 
were developed using the European Cooperative Acute 
Stroke Study II (ECASS II) definition of SICH, i.e. ICH 
with worsening in the NIHSS score of ≥ 4.5 The GRASPS 
score was developed using the National Institute of 
Neurological Disorder and Stroke (NINDS) definition: 
any ICH with a worsening in the NIHSS score of ≥ 1.11 
The SITS score uses the SITS-MOST definition, i.e. a 
local or remote parenchymal haemorrhage (PH2, a 
haemorrhage > 30% of the infarcted area with significant 
space-occupying effect)12 and worsening of NIHSS ≥ 4.11
Predictor variables
The following variables were extracted from the SITS 
database to evaluate significant univariate predictors of 
SICH and any ICH: age; gender; weight; systolic and 
diastolic blood pressures; baseline NIHSS score; glucose; 
cholesterol; prior previous stroke or transient ischaemic 
attack; history of hypertension; diabetes mellitus; chronic 
heart failure; atrial fibrillation; use of anti-hypertensive, 
anti-platelet or statin medication; symptom onset to 
treatment time, presence of a hyperdense middle cerebral 
artery (HDMCA) on CT scan and ASPECTS score. 
Statistical analysis 
Data are presented as either means or percentages 
unless otherwise stated. Comparisons between groups 
were made using the Chi-square test and t-test where 
appropriate with significance defined as p < 0.05. 
Risk score 
(range of scores)
Variables comprising each score
(points for score variable)
SEDAN
(0–6)
• Admission blood glucose: ≥ 
12mmol/L (2); 8.1–12mmol/L (1)
• Presence of early infarct sign on CT 
scan (1)
• HDMCA on CT scan (1)
• Age ≥75 years (1)
• NIHSS ≥10 (1)
HAT
(0-5)
• Diabetes mellitus or admission 
blood glucose >200 mg/dL (1)
• NIHSS: ≥20 (2); 15–19 (1)
• Fraction of MCA territory 
hypodensity: >1/3 (2); 1/3 (1)
SITS
(0–12)
• NIHSS: ≥13 (2); 7–12 (1)
• Age ≥72 years (1)
• Systolic Blood Pressure ≥146mmHg 
(1)
• Weight ≥95 kilograms (1)
• Blood glucose ≥10mmol/L (2)
• Pre-stroke anti-coagulant therapy: 
aspirin and clopidogrel therapy (3); 
aspirin monotherapy (2)
• Pre-stroke hypertension (1)
• Onset-to-treatment time ≥180 
minutes (1)
GRASPS
(45–101)
• Age (years): >80 (17); 71–80 (15); 
61–70 (11); ≤60 (8)
• NIHSS: >20 (42); 16–20 (40); 11–15 
(34); 6–10 (27); 0–5 (25)
• Systolic blood pressure (mmHg): 
≥180 (21); 150–179 (18); 120–149 
(14); <120 (10)
• Blood glucose (mg/dL): ≥150 (8); 
100–149 (6); <100 (2)
• Race: Asian (9); Non-Asian (0)
• Gender: Male (4); Female (0)
HDMCA: hyperdense middle cerebral artery; CT: computerised 
tomography; NIHSS: National Institutes of Health Stroke Scale; 
MCA: middle cerebral artery.
table 1 Variables contributing to calculation of each risk 
score
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Univariate analysis was performed to identify potential 
variables associated with SICH in our population. 
Multivariate analysis was not performed in view of the 
sample size, and because we wanted to test previously 
established risk scores rather than develop any new 
predictive models or scores. We conducted a post-
hoc bootstrapping analysis of 1000 iterations to 
compare the predictive performances of the four 
SICH risk scores using the area under the receiver-
operator curve (AUROC).13 An AUROC=0.5 indicates 
the risk score performs no better than chance, 
whereas an AUROC of 1 indicates perfect discrimin-
ation. The best risk score was defined as the score 
with the largest statistically significant AUROC using 
analyses of variance.14 Analyses were conducted using 
SAS software, version 9.3 (SAS Institute, Inc., Cary, 
NC, USA).
results
Data on a total of 431 acute ischaemic stroke patients 
who received intravenous alteplase and were entered 
into the SITS database were analysed in this study. From 
comparison SITS data the baseline stroke severity and 
characteristics are similar to other patients receiving 
thrombolysis in the UK (mean age 70 vs 70 years, 78% 
free of disability pre-stroke [modified Rankin score <2] 
vs 86%, NIHSS 10 vs 12 and 40% total anterior circulation 
syndrome vs 46% respectively). Any ICH occurred in 
12% (53/413) of patients; of these only 11% (6/53) 
fulfilled the SITS-MOST definition of SICH,11 34% (18/53) 
the ECASS II definition,4 and 43% (23/53) the NINDS 
definition.10 Mean NIHSS significantly improved in 
patients without ICH after 24 hours (10.8 [SD 6.6] to 
8.0 [SD 7.8], p < 0.0001), whereas there was a non-
all
(n=431)
any haemorrhage 
(n=54)
NINDS SICH 
Definition1 (n=23)
eCaSS II SICH 
Definition2 (n=18)
Age (years) (SD) 70.1 (13.6) 76.2*** (10.4) 77.9 (9.3) 77.2** (9.8)
Male (%) 191 (44) 35 (65) 13 (57) 11 (61)
Weight (kg) (SD) 76.3 (16.6) 76.9 (18.3) 73.6 (17.3) 71.5 (17.1)
Systolic blood pressure 
(mmHg) (SD)
150.8 (21.9) 156.4 (19.1) 156.7 (16.5) 153.5* (16.1)
Diastolic blood pressure 
(mmHg) (SD)
80.7 (13.6) 83.4 (11.0) 82.4 (11.0) 80.9 (11.8)
Baseline NIHSS3 (SD) 11.2 (6.7) 14.0* (6.0) 16.5**(6.1) 14.8*** (5.4)
24 hours NIHSS (SD) 8.9 (8.5) 15.1*** (10.3) 26.8*** (4.9) 27.5*** (5.3)
Onset to treatment 
time (min) (SD)
161.3 (57.7) 161 (61.4) 155.6 (71.1) 153.5 (71.4)
Glucose (mmol/L) (SD) 6.8 (2.2) 7.5(2.5) 7.7 (2.9) 7.9 (3.3)
Cholesterol (mmol/L) 
(SD)
4.5 (1.3) 4.2(1.0) 4.1 (1.3) 3.7 (0.6)
Previous stroke/TIA4 (%) 72/367 (20) 16/49 (33)* 6/23 (26) 5/18 (28)
Hypertension (%) 200/369 (54) 29/49 (59) 13 (57) 10 (56)
Diabetes mellitus (%) 61/410 (15) 13/52 (25)* 8 (35)** 6 (33)*
Chronic heart failure (%) 22/369 (6) 5/49 (10)*** 2 (9) 1 (6)
Current non-smoking 
status (%)
201/367 (55) 46/49 (94)** 19 (83) 14 (78)
Atrial fibrillation (%) 84/370 (24) 17/49 (35)* 6 (26) 5 (28)
Anti-hypertensive 
medication (%)
169/365 (46) 26/49 (53) 14 (61) 11 (61)
Anti-platelet medication 
(%)
132/348 (38) 30/48 (63)*** 16 (70)* 14 (78)***
Statin medication (%) 93/365 (26) 14/49 (29) 6 (26) 5 (28)
HDMCA5 (%) 114/430 (27) 19/53 (36) 10 (46)* 6 (35)
ASPECTS6 (SD) 9.3 (1.2) 8.6*** (1.5) 7.7*** (2.6) 7.8*** (2.5)
Means are expressed with standard deviations. Percentages are expressed with numerator and denominator. 
*p<0.05; **p<0.01; ***p<0.001
1Any haemorrhage with worsening of NIHSS ≥ 1; 2Any haemorrhage with worsening of NIHSS ≥ 4; 3National Institutes of Health 
Stroke Scale; 4Transient ischaemic attack; 5Hypodense middle cerebral artery; 6Alberta Stroke Programme Early Computerised 
Tomography Score
table 2 Univariate analysis to determine possible factors predisposing to any intracerebral haemorrhage and SICH 
following thrombolysis
Predicitive scores for SICH after stroke thrombolysis
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significantly increased NIHSS in patients who had any 
ICH (17.0 [SD 10.8] vs 14.0 [SD 6.1], p=0.08). Univariate 
analysis identified several significant predictors of SICH 
as defined by NINDS and ECASS II definitions following 
thrombolysis (Table 2); age, glucose, NIHSS, diabetes 
mellitus, HDMCA on CT scan, ASPECTS score and anti-
platelet therapy prior to stroke onset.
Only six patients fulfilled the SITS-MOST definition of 
ICH (clinical data not shown in view of lack of statistical 
power). Additional univariate predictors for developing 
any ICH include previous cerebral ischaemic event, non-
smoking status, congestive cardiac failure and atrial 
fibrillation. Onset to treatment time, gender, glucose 
levels and anti-hypertensive medication were not 
significant predictors. 
The median values for the following scores are: SEDAN 
2 (inter-quartile ratio [IQR] 1–2); HAT 1 (IQR 0–2); 
GRASPS 69 (IQR 62–75) and SITS 4 (IQR 3–6). The HAT 
score was the best predictor score regardless of 
definition of SICH (Table 3). The SITS score was the next 
best for an ECASS II definition of SICH whereas the 
GRASP score was the next best for the NINDS 
definition.
dIscussIon
This study aimed to compare the accuracy of four 
different scoring systems to predict SICH in patients 
admitted to our hospital following thrombolysis. The 
HAT score is the simplest and best performing risk score 
regardless of SICH definition. This suggests that the 
variables used in this score (i.e. diabetes mellitus or 
glucose level, stroke severity and extent of early ischaemic 
change) are the strongest independent predictors of 
SICH. Higher NIHSS (i.e. stroke severity) likely correlates 
with the volume of ischaemic tissue at risk for 
haemorrhagic transformation.15 The degree of visible 
hypodensity on the pre-treatment CT is thought to 
represent cytotoxic oedema and possible irreversible 
injury, which is associated with ICH after thrombolysis.16 
Experimental studies showed that diabetes mellitus and 
hyperglycaemia are associated with blood–brain barrier 
and microvascular impairments, as well as increased 
haemorrhagic infarct conversion after reperfusion.17 A 
recent meta-analysis  suggests that admission glucose 
but no prior diabetes predicts post-thrombolysis SICH.18 
However, admission glucose may be a surrogate marker 
of brain infarction severity (as a stress response) rather 
than a causal factor. 
Our population variables, such as onset to treatment 
time, age, blood pressure or hypertension and gender 
add little predictive power. This is despite some of these 
variables being univariate predictors of any ICH in our 
population. Variables found to be significant predictors in 
univariate analysis may be associated with SICH, but may 
not be causally related. Multivariate analysis, as used in 
development of SICH predictor scores (e.g. HAT or 
SEDAN), identifies independent predictor variables. 
Many of these predictors (e.g. age, gender, non-smoking 
status and chronic heart failure) have been found in 
previous studies to be risk factors for ICH, although not 
necessarily SICH post-thrombolysis.11 In particular, 
although blood pressure is a variable in the GRASPS and 
SITS scores, a recent meta-analysis of studies of SICH 
could not identify blood pressure even as a significant 
univariate predictor.19 Onset to treatment time is a 
significant factor in estimating the benefit of thrombolysis 
with an approximate halving of benefit every 90 minutes. 
The risk of SICH appears mostly constant in the 0–6 
hour time window, which may be one reason the SITS 
score performs less well than the HAT score.3,19,20 The 
majority of patients (96%) in this series were treated 
with intravenous thrombolysis within the current 
accepted time window of within 4.5 hours of symptom 
onset. Systems should be optimised to maximise early 
delivery of stroke thrombolysis to maximise benefit. We 
did not find any difference in ASPECTS score with regard 
to onset to treatment time (data not shown), but the 
degree of appearance of early ischaemic change should 
be time-dependent, although other factors such as 
collateral circulation may affect ASPECTS score. 
A meta-analysis by Whiteley et al.19 showed that factors 
which may predict SICH following thrombolysis are 
those which also predict poor outcome following a 
stroke. The authors further concluded that predicting 
which patients will develop SICH may be difficult. Those 
patients predicted to have a high risk of SICH may not 
have a poor outcome following thrombolysis, and so 
clinical decision making is difficult.19 A further recent 
analysis of patients from the third International Stroke 
Trial (IST-3) trial demonstrates that patients predicted to 
be at highest risk of developing SICH still achieve a net 
population benefit from receiving thrombolysis.21 Similar 
SICH risk 
prediction 
scores
AUROC of SICH Definitions
S I T S - M O S T 
(n=6)
ECASS II
(n=8)
NINDS
(n=23)
SEDAN 0.62
(0.61–0.63)
0.67
(0.65–0.69)
0.72
(0.71–0.73)
HAT 0.67
(0.65–0.69)
0.73
(0.71–0.75)
0.78
(0.75–0.81)
GRASPS 0.65
(0.63–0.67)
0.69
(0.66–0.70)
0.74
(0.72–0.76)
SITS 0.68
(0.66–0.69)
0.72
(0.70–0.74)
0.72
(0.70–0.73)
table 3 Area under the receiver-operator curve values for 
the definitions of symptomatic intracerebral haemorrhage. 
Data expressed as mean (95% CI).
T Watson-Fargie, D Dai, MJ MacLeod et al.
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results to those found in this paper have been 
demonstrated by Strbian et al.,22 who showed that the 
SEDAN scorehad the highest predictive power in 3012 
patients with a 7.3% rate of SICH. They also concluded 
that none of the predictive scores they assessed, 
including HAT, SEDAN, GRASPS and SITS, had better 
than moderate performance when analysed using the 
area under the curve, similar to the findings from IST-3.21 
This current study had some limitations. Patients 
admitted to a single stroke unit were studied and it is 
uncertain whether this study population is generalisable. 
Despite this the demographics and stroke severity of 
patients treated at our centre were similar to the 
average UK patient. Furthermore, this study may be 
underpowered for some of the analyses. The differing 
SICH definitions are a further limitation as this prevents 
precise comparison between SICH prediction scores. 
There is debate as to which SICH definition is the most 
relevant. The SITS-MOST definition seems a very narrow 
definition, being present in only 1.4% of the patients in 
this study, whereas the NINDS definition is too liberal as 
NIHSS can worsen by 1 point purely due to oedema 
after acute ischaemic stroke. The ECASS II definition is 
recognised as being the most pertinent in predicting 
poor and fatal outcomes.23 Furthermore it is clear that 
minor haemorrhages (e.g. PH1), which can be excluded 
from some SICH definitions, may be associated with 
worse outcomes, and survivors of SICH tend to have 
poorer outcomes.23 
In conclusion, this study demonstrates that age, glucose, 
stroke severity (as defined by the NIHSS score), diabetes 
mellitus, HDMCA on CT scan, ASPECTS and prior anti-
platelet therapy are univariate predictors of developing 
SICH. The HAT score uses the simplest variables and 
appears to have the best predictive value for SICH in this 
population, regardless of definition. Despite this the HAT 
score does not assess overall benefit of thrombolytic 
therapy in addition to risk of harm. In particular it is 
notable that the increase in mortality at 7 days after 
thrombolysis, mostly due to SICH, appears to be negated 
by improved survival at six months in both the IST-3 
trial24 and the most recent systematic review of alteplase 
for ischaemic stroke. Further studies are required to 
determine whether SICH prediction scores should 
influence clinical decision-making in regard to the use of 
thrombolytic therapy for AIS. At a minimum, the HAT 
score could be used to estimate the risk of SICH in a 
given patient when discussing the risk and benefit of 
thrombolysis with stroke patients or their relatives.
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